Taub Rebecca has demonstrated a pronounced selling bias in recent transactions involving Madrigal Pharmaceuticals (MDGL), according to SEC Form 4 filings. Over 69 reported trades, Rebecca has sold $48.06 million worth of MDGL shares while purchasing only $1.31 million, reflecting a nearly 37-to-1 ratio of sell-to-buy value. The activity has been exclusively concentrated in MDGL, with no trades in other companies. Recent filings show a surge in selling, with 24 disposals since January 2026 and no buys. The largest single sale occurred on January 20, 2026, unloading $1.1 million in shares, followed by multiple six-figure transactions on January 9, 2026, including a $781,903 sale and a $699,623 sale. The only non-sale transaction in this period was a minor $3,792 market acquisition on January 9, 2026, dwarfed by the $503,106 sale executed the same day.
The selling pattern accelerated in early 2026, with 22 of the 24 recent sales occurring on January 9 alone, totaling approximately $6.3 million across transactions ranging from $15,931 to $781,903. Two additional sales followed later in January ($318,596 and $1.1 million) and one in March 2026 ($212,083). The consistency and scale of disposals suggest an ongoing reduction in MDGL exposure, with no offsetting purchases to balance the activity. While the filings don’t specify Rebecca’s role at Madrigal, the transactional history indicates a sustained exit from the position over time, particularly in the first quarter of 2026.
AI-assisted summary